Biophage Pharma appoints new Chief Financial Officer



    MONTREAL, April 11 /CNW Telbec/ - Biophage Pharma Inc. (TSX.V: BUG) a
biotechnology company focused on the development of innovative phage-based
products for the diagnosis, prevention and control of bacteria contaminations,
is pleased to announce the appointment of Mr. Louis Guindon as Chief Financial
Officer and Treasurer of the Corporation.
    With more than 12 years of experience in Corporate Financing, Mergers and
Acquisitions, Investor relations and Corporate Development Initiatives,
Mr. Guindon will be a big asset to Biophage in its current period of active
growth. Louis replaces the corporation's interim CFO, Mr. Myer Bentob, who
will remain an active member of the Board.
    Mr. Guindon is the founder of Wildon-LJJ inc. a corporate financial
services provider offering financial advisory and analytical support to its
clients' senior management. Prior to joining Biophage, Mr. Guindon worked at
20-20 Technologies as V.P. Corporate Development, Desjardins Securities, CIBC
World Markets and RBC Capital Markets.
    "I am very pleased that Mr. Guindon has accepted to act as Chief
Financial Officer and Treasurer of the Corporation. Louis brings a wealth of
entrepreneurial business experience to our team and his expertise in corporate
governance and corporate financing will be invaluable in the development and
commercialization of our products and services," said Dr. Rosemonde
Mandeville, President and Chief Executive Officer of Biophage. "We would like
to thank Mr. Bentob for his excellent work performed in the past few years and
the important changes he has contributed in restructuring our financial
services. We also appreciate his continued interest and active involvement as
a member of our Board of Directors." continued Dr. Mandeville.

    About Biophage Pharma Inc.

    Biophage Pharma is a high potential, revenue-driven Canadian
biotechnology company focused on the development of innovative phage-based
products and technologies for the detection, prevention and control of
bacterial infections. Founded in 1995, Biophage operates three divisions:
(1) The Biosensors division for the development and commercialization of
Biosensors, more particularly a portable PDS96(R) Biosensor which is now in
the pre-commercialization stage; (2) The phage therapy division for the
prevention and control of bacterial contaminations in the medical, veterinary
and environment fields; (3) The Immunotox Labs division, which provides
services in Immunogenicity and Immunotoxicity, Beryllium sensitivity testing
and MELISA(R) testing for the detection of sensitization to more than
200 different allergens including metals, penicillin, gluten and pollens.
    (www.biophagepharma.net; www.immunotoxlabs.net)

    The TSX Venture Exchange does not accept responsibility for the adequacy
    or accuracy of this release.
    %SEDAR: 00014714EF




For further information:

For further information: Biophage Pharma Inc.: Rosemonde Mandeville,
M.B., Ch.B., PhD., President and Chief Executive Officer, Biophage Pharma
Inc., (514) 496-1488, rosemonde.mandeville@biophagepharma.com; Renmark
Financial Communications Inc.: Investor Relations: Christine Stewart,
cstewart@renmarkfinancial.com; Maurice Dagenais,
mdagenais@renmarkfinancial.com; (514) 939-3989, Fax: (514) 939-3717;
www.renmarkfinancial.com

Organization Profile

BIOPHAGE PHARMA, INC.

More on this organization


Custom Packages

Browse our custom packages or build your own to meet your unique communications needs.

Start today.

CNW Membership

Fill out a CNW membership form or contact us at 1 (877) 269-7890

Learn about CNW services

Request more information about CNW products and services or call us at 1 (877) 269-7890